Live Stream Preview | From 1 to Infinity: Unlocking the Infinite Possibilities of Cell Culture!
Release Date:
2025-05-19 15:13
Shanghai Hycells Biotechnology is a biotechnology innovation company specializing in primary immune cell research, dedicated to providing customers with comprehensive, one-stop solutions for immune cells and stem cells. We offer compliant, ethically sound immune cell and stem cell collection services, while also launching High-quality, safe, and reliable HiXpan Registered trademark Serum-Free Culture Kit Series , empowering high-quality research on cellular biology and clinical applications. Hycells HiXpan Registered trademark We have achieved domestic production across the entire value chain for culture-based products, from biological raw materials to finished formulations, leveraging the domestic supply chain to build a complete industrial ecosystem. Our processes rigorously adhere to ISO standards for raw material selection, manufacturing management, and quality control. The resulting products enable the generation of immune cells with high purity and robust expansion efficiency, eliminating the need for feeder cells and thereby minimizing batch-to-batch variability and microbial contamination. Formulated without serum or animal-derived components, these products meet GMP and IND submission requirements, reducing regulatory risks.
On May 16, 2025, from 11:00 a.m. to 11:30 a.m., MedMai Premium will host a special live session on cutting-edge cell-culture products. Mr. Huang Xin, Product Technology Manager at Heyou Bio, will provide an in-depth analysis of the technical advantages of the HiXpan® product, covering everything from 1 to ∞, unlocking limitless possibilities for your cell culture!
Main Lecturer: Huang Xin
Co-founder & Product Technology Manager
Report Topic: Dual-Core Drive—NK and γδ T cells Innovations in Amplification Technology and the Future of the Industry
With nearly a decade of deep expertise in the field of cell therapy, the company is committed to technological innovation and its industrial application. It possesses end-to-end capabilities spanning from basic research to commercialization, with a keen understanding of emerging trends in the cell therapy industry. The team combines rigorous scientific thinking with a strong business orientation, excelling in building robust technology platforms and leading high-performing teams. In 2021, the company joined Hycells, where it was responsible for establishing the company’s technical and quality management systems, covering the entire workflow from cell preparation and quality control analysis to process development. The focus has been on optimizing primary cell manufacturing processes, developing standardized operating procedures, and significantly enhancing production efficiency and batch-to-batch consistency. This effort has resulted in multiple invention patents and utility model patents, thereby establishing core technological barriers. Prior to joining Hycells, the individual held positions at Vitong Lihua Laboratory Animal Technology Co., Ltd., where they solidified their foundation in cell culture and biological assay techniques, built cell isolation, preparation, and quality control platforms, and formulated standardized operating procedures. Standard Operating Procedure ).
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board